Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 5/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL876781 | 0.85 | NR1H4 (0.41) | PLATNR1H4HTR2CKDM1AUSP7 | |
| SCHEMBL12506048 | 0.83 | PLAT (0.45) | PLATNR1H4KDM1ACNR2USP7 | |
| SCHEMBL20066201 | 0.76 | PLAT (0.33) | PLAT | |
| SCHEMBL14450216 | 0.76 | CNR2 (0.37) | CNR2 | |
| SCHEMBL24844540 | 0.73 | NR1H4 (0.61) | PLATNR1H4HTR2C | |
| SCHEMBL7827521 | 0.73 | NR1H4 (0.48) | PLATNR1H4HTR2CKDM1AUSP7 | |
| SCHEMBL24844623 | 0.73 | NR1H4 (0.57) | PLATNR1H4HTR2CCNR2 | |
| SCHEMBL20969925 | 0.73 | CNR2 (0.36) | CNR2 | |
| SCHEMBL12070397 | 0.73 | USP7 (0.50) | PLATNR1H4KDM1ACNR2USP7 | |
| SCHEMBL979120 | 0.73 | NR1H4 (0.47) | PLATNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| WO-2018069732-A1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | PLAT 3295/4885NR1H4 184/4885HTR2C 311/4885 |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | PLAT 4415/4885NR1H4 149/4885HTR2C 346/4885 |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | PLAT 4415/4885NR1H4 149/4885HTR2C 346/4885 |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | PLAT 4415/4885NR1H4 149/4885HTR2C 346/4885 |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | PLAT 4415/4885NR1H4 149/4885HTR2C 346/4885 |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | PLAT 4415/4885NR1H4 149/4885HTR2C 346/4885 |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | PLAT 4337/4885NR1H4 47/4885HTR2C 509/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | PLAT 4415/4885NR1H4 149/4885HTR2C 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.